J&J CEO Now Sees 'Line of Sight' to Double-Digit Growth for His $100 Billion Company. Here's Why Investors Should Pay Attention.
Johnson & Johnson is a healthcare giant, but an opportunity to invest in the United States and a plethora of big products suggest it still has growth appeal.
Overview
Johnson & Johnson (NYSE: JNJ) is one of the most recognized names in the healthcare sector. It is a Dividend King with over 50 consecutive annual dividend increases and operates in both the pharmaceutical and medical device segments of the broader healthcare sector. And the company believes it has both the foundation and the opportunity to grow at double-digit rates. Here's what CEO Joaquin Duato wants you to know.
J&J has 28 platforms generating $1 billion in revenue each, according to CEO Duato, who recently spoke to Fox News about his company's growth prospects. That's a powerful foundation for the company to support its research and development efforts. Notably, the company isn't reliant on just one segment of the broader healthcare sector, as it is a leader in both the drug and medical device segments.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.